[go: up one dir, main page]

GT200900008A - Derivados novedosos de aminopiridina que tienen acción inhibidora selectiva sobre aurora a - Google Patents

Derivados novedosos de aminopiridina que tienen acción inhibidora selectiva sobre aurora a

Info

Publication number
GT200900008A
GT200900008A GT200900008A GT200900008A GT200900008A GT 200900008 A GT200900008 A GT 200900008A GT 200900008 A GT200900008 A GT 200900008A GT 200900008 A GT200900008 A GT 200900008A GT 200900008 A GT200900008 A GT 200900008A
Authority
GT
Guatemala
Prior art keywords
aminopiridine
novedous
aurora
derivatives
inhibitory action
Prior art date
Application number
GT200900008A
Other languages
English (en)
Inventor
Iwasawa Yoshikazu
Kato Tetsuya
Kawanishi Nobuhiko
Masutani Kouta
Mita Takashi
Nonoshita Katsumasa
Ohkubo Mitsuru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT200900008A publication Critical patent/GT200900008A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • C07D241/22—Benzenesulfonamido pyrazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A DERIVADOS NOVEDOSOS DE AMINOPIRIDINA QUE SON ÚTILES EN EL CAMPO FARMACÉUTICO YA QUE INHIBEN EL CRECIMIENTO DE CÉLULAS TUMORALES EN BASE A UNA ACCIÓN INHIBIDORA SELECTIVA DE LA AURORA A Y MUESTRAN EFECTO ANTITUMORAL.
GT200900008A 2006-08-31 2009-01-13 Derivados novedosos de aminopiridina que tienen acción inhibidora selectiva sobre aurora a GT200900008A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2006236472 2006-08-31
US92608607P 2007-04-25 2007-04-25

Publications (1)

Publication Number Publication Date
GT200900008A true GT200900008A (es) 2010-10-04

Family

ID=39136042

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200900008A GT200900008A (es) 2006-08-31 2009-01-13 Derivados novedosos de aminopiridina que tienen acción inhibidora selectiva sobre aurora a

Country Status (27)

Country Link
US (2) US20100016335A1 (es)
EP (2) EP2062887B1 (es)
JP (3) JP2008081492A (es)
KR (1) KR20090055562A (es)
CN (1) CN101528731B (es)
AR (1) AR062585A1 (es)
AU (1) AU2007289609B2 (es)
CA (1) CA2657469C (es)
CL (1) CL2007002519A1 (es)
CO (1) CO6190529A2 (es)
CR (1) CR10553A (es)
EC (1) ECSP099062A (es)
ES (1) ES2389515T3 (es)
GT (1) GT200900008A (es)
HN (1) HN2009000113A (es)
IL (1) IL196497A0 (es)
MA (1) MA30719B1 (es)
MX (1) MX2009000390A (es)
NO (1) NO20091301L (es)
NZ (1) NZ574081A (es)
PE (1) PE20080835A1 (es)
RU (1) RU2437880C2 (es)
SV (1) SV2009003152A (es)
TW (1) TW200817363A (es)
UA (1) UA95972C2 (es)
WO (2) WO2008026768A1 (es)
ZA (1) ZA200900126B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5411152B2 (ja) * 2008-02-22 2014-02-12 Ｍｓｄ株式会社 オーロラａ選択的阻害作用を有する新規アミノピリジン誘導体
CN102046631A (zh) * 2008-03-31 2011-05-04 阳光医药工业有限公司 制备吗啡烷类似物的改良方法
JP5683462B2 (ja) * 2008-07-24 2015-03-11 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ オーロラキナーゼ阻害剤および抗増殖剤を含む治療用組み合わせ
NZ623069A (en) * 2009-08-17 2015-11-27 Sloan Kettering Inst Cancer Heat shock protein binding compounds, compositions, and methods for making and using same
JP5878178B2 (ja) 2011-09-30 2016-03-08 大鵬薬品工業株式会社 １，２，４−トリアジン−６−カルボキサミド誘導体
TWI485146B (zh) * 2012-02-29 2015-05-21 Taiho Pharmaceutical Co Ltd Novel piperidine compounds or salts thereof
US9630896B2 (en) 2013-11-22 2017-04-25 Tansna Therapeutics, Inc. 2,5-dialkyl-4-H/halo/ether-phenol compounds
EA201692155A1 (ru) 2014-05-13 2017-04-28 Мемориал Слоун-Кеттеринг Кэнсэ Сентр МОДУЛЯТОРЫ Hsp70 И СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ
TWI693218B (zh) 2014-11-14 2020-05-11 美商美國禮來大藥廠 極光ａ激酶抑制劑
CN107251007B (zh) * 2015-03-25 2021-10-01 英特尔公司 集群计算服务确保装置和方法
CN108250191B (zh) * 2018-03-15 2020-10-20 兰州大学 一种3,5-二取代的2-氨基-吡嗪化合物及其制备工艺与应用
WO2020049208A1 (es) 2018-09-09 2020-03-12 Fundacio Privada Institut De Recerca De La Sida - Caixa Aurora cinasa como diana para tratar, prevenir o curar una infección por vih o sida
CN112898292A (zh) * 2019-12-03 2021-06-04 微境生物医药科技(上海)有限公司 新型极光激酶抑制剂及其用途
TWI785474B (zh) * 2020-01-22 2022-12-01 大陸商北京加科思新藥研發有限公司 用作選擇性Aurora A抑制劑的新型雜環化合物
US20250249019A1 (en) 2022-04-08 2025-08-07 Eli Lilly And Company Method of treatment including kras g12c inhibitors and aurora a inhibitors

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
OA07174A (fr) 1981-08-24 1984-04-30 May & Baker Ltd Nouvelles imidazotétrazionones, leur préparation et les médicaments qui les contiennent.
JPS6019790A (ja) 1983-07-14 1985-01-31 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5223608A (en) 1987-08-28 1993-06-29 Eli Lilly And Company Process for and intermediates of 2',2'-difluoronucleosides
ES2137932T3 (es) 1990-09-28 2000-01-01 Smithkline Beecham Corp Procedimiento para la preparacion de analogos de camptotecina solubles en agua, asi como los compuestos 10-hidroxi-11-alcoxi-6-camptotecina.
US5247089A (en) 1990-12-20 1993-09-21 North Carolina State University Method of making intermediates useful for the manufacture of camptothecin and camptothecin analogs
US5191082A (en) 1990-12-20 1993-03-02 North Carolina State University Camptothecin intermediate and method of making camptothecin intermediates
US5162532A (en) 1990-12-20 1992-11-10 North Carolina State University Intermediates and method of making camptothecin and camptothecin analogs
US5200524A (en) 1990-12-20 1993-04-06 North Carolina State University Camptothecin intermediates and method of making same
US5243050A (en) 1990-12-20 1993-09-07 North Carolina State University Alkylpyridone DE ring intermediates useful for the manufacture of camptothecin and camptothecin analogs
EP1238986B1 (en) 1992-10-28 2008-06-25 Genentech, Inc. Use of Vascular endothelial cell growth factor antagonists
JP3025602B2 (ja) 1993-05-21 2000-03-27 デビオファーム エス．アー． 光学的に高純度なシス−オキザラート（トランス−ｌ−１，２−シクロヘキサンジアミン）白金（ＩＩ）錯体の製造方法
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
CA2222231A1 (en) 1995-06-07 1996-12-19 Imclone Systems Incorporated Antibody and antibody fragments for inhibiting the growth of tumors
JP3154399B2 (ja) 1996-07-04 2001-04-09 デビオファーム エス．アー． 白金化合物の製造方法
PE92198A1 (es) 1996-08-01 1999-01-09 Banyu Pharma Co Ltd Derivados de 1,4-piperidina disustituida que contienen fluor
ATE309241T1 (de) * 1999-09-10 2005-11-15 Merck & Co Inc Tyrosin kinase inhibitoren
AU2002213467A1 (en) 2000-10-11 2002-04-22 Chemocentryx, Inc. Modulation of ccr4 function
US20020137755A1 (en) 2000-12-04 2002-09-26 Bilodeau Mark T. Tyrosine kinase inhibitors
CA2432222C (en) 2000-12-21 2008-07-29 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
RU2332415C2 (ru) * 2001-04-27 2008-08-27 Вертекс Фармасьютикалз Инкорпорейтед Производные пиразола, полезные в качестве ингибиторов протеинкиназы
WO2002094264A1 (en) 2001-05-23 2002-11-28 Tularik Inc. Ccr4 antagonists
EP1754706A4 (en) * 2004-05-21 2010-08-18 Banyu Pharma Co Ltd SELECTIVE INHIBITORS FOR CDK4 AND CDK6 WITH AMINOTHIAZOLSKELETT
EP1828165B1 (en) * 2004-10-29 2013-03-20 Msd K.K. Novel aminopyridine derivatives having aurora a selective inhibitory action
US7491720B2 (en) * 2004-10-29 2009-02-17 Banyu Pharmaceutical Co., Ltd. Aminopyridine derivatives having Aurora A selective inhibitory action
TW200628463A (en) 2004-11-10 2006-08-16 Synta Pharmaceuticals Corp Heteroaryl compounds
GB0428082D0 (en) 2004-12-22 2005-01-26 Welcome Trust The Ltd Therapeutic compounds
CA2589830A1 (en) 2005-01-05 2006-07-13 Rigel Pharmaceuticals, Inc. Ubiquitin ligase inhibitors
EP1876178B1 (en) * 2005-04-28 2015-05-27 Mitsubishi Tanabe Pharma Corporation Cyanopyridine derivative and use thereof as medicine
WO2006124874A2 (en) 2005-05-12 2006-11-23 Kalypsys, Inc. Inhibitors of b-raf kinase
WO2006129842A1 (ja) * 2005-06-01 2006-12-07 Banyu Pharmaceutical Co., Ltd. オーロラa選択的阻害作用を有する新規アミノピリジン誘導体
US7572809B2 (en) * 2005-12-19 2009-08-11 Hoffmann-La Roche Inc. Isoquinoline aminopyrazole derivatives

Also Published As

Publication number Publication date
AU2007289609B2 (en) 2012-02-02
ECSP099062A (es) 2009-02-27
AR062585A1 (es) 2008-11-19
TW200817363A (en) 2008-04-16
NO20091301L (no) 2009-04-30
RU2437880C2 (ru) 2011-12-27
NZ574081A (en) 2011-08-26
SV2009003152A (es) 2009-04-28
ES2389515T3 (es) 2012-10-26
US7915263B2 (en) 2011-03-29
ZA200900126B (en) 2010-01-27
CN101528731B (zh) 2014-05-07
JP2008081492A (ja) 2008-04-10
JP5256168B2 (ja) 2013-08-07
WO2008026769A1 (en) 2008-03-06
IL196497A0 (en) 2009-09-22
CO6190529A2 (es) 2010-08-19
CR10553A (es) 2009-06-28
MX2009000390A (es) 2009-01-29
PE20080835A1 (es) 2008-06-14
WO2008026768A1 (en) 2008-03-06
US20080058347A1 (en) 2008-03-06
CN101528731A (zh) 2009-09-09
RU2009111599A (ru) 2010-10-10
EP2062887A4 (en) 2010-03-31
EP2061782A4 (en) 2010-03-31
JP2010047602A (ja) 2010-03-04
CA2657469C (en) 2013-07-02
JP4466782B2 (ja) 2010-05-26
HN2009000113A (es) 2014-01-06
CL2007002519A1 (es) 2008-02-08
MA30719B1 (fr) 2009-09-01
EP2062887A1 (en) 2009-05-27
US20100016335A1 (en) 2010-01-21
AU2007289609A1 (en) 2008-03-06
UA95972C2 (ru) 2011-09-26
KR20090055562A (ko) 2009-06-02
EP2061782A1 (en) 2009-05-27
JPWO2008026769A1 (ja) 2010-01-21
EP2062887B1 (en) 2012-07-04
CA2657469A1 (en) 2008-03-06

Similar Documents

Publication Publication Date Title
GT200900008A (es) Derivados novedosos de aminopiridina que tienen acción inhibidora selectiva sobre aurora a
NO2020028I1 (no) saksagliptin og dapagliflozin
CO2019007888A2 (es) Inhibidores selectivos de jak1
CY2014012I2 (el) Χορηγηση αναστολεων διπεπτιδυλοπεπτιδασης
SV2009003335A (es) Formulaciones para el cancer
PT1849470T (pt) Fármaco anticancro contendo alfa, alfa, alfa-trifluorotimidina e inibidor da timidina-fosforilase
EP2167492A4 (en) NEW AMID DERIVATIVE FOR INHIBITING THE GROWTH OF CANCER CELLS
CY1118062T1 (el) Συνθεσεις για την αντιμετωπιση της ναυτιας και του εμετου κεντρικης προελευσης
GT200900146A (es) Inhibidores de la actividad de la akt
DK3120862T3 (da) Antimikrobielt peptid og sammensætninger deraf
CL2012001080A1 (es) Dispersión sólida de rifaximina y un portador farmacéuticamente aceptable; composición farmacéutica; uso en el tratarmiento y/o prevención de una infecciíon microbiana que comprende la administración de la dipersión sólida.
CR11299A (es) Amidas heterociclicas utiles para el tratamiento de cancer y psoriasis
ECSP088440A (es) Imidazopirazinas como inhibidores de proteinquinasa
ATE499109T1 (de) Zusammensetzung zur proteasomhemmung
CL2008001633A1 (es) Compuestos derivados de pirrolidin-3-carboxamida; composición farmacéutica; y uso comominhibidores de erk para el tratamiento del cancer.
ATE492272T1 (de) Therapeutische antimikrobielle zusammensetzungen und methoden
DK2107905T3 (da) Fast sammensætning omfattende alogliptin og pioglitazon
ECSP10010361A (es) Derivados de piridazinona
BRPI0819573A2 (pt) Composição e artigo
CR20110476A (es) Compuestos y usos de los mismos
CR10277A (es) Pirazolquinolonas como potentes inhibidores de parp
GT201200111A (es) Piperidinas sustituidas que aumentan la actividad de p53 y sus usos
GT200900284A (es) Dosis intravenosa y oral de un inhibidor p2y12 de accion directa y reversible.-
EA021554B9 (ru) Органические соединения и их применение для лечения hcv инфекции
PL2535716T3 (pl) Marker nowotworowy i cel terapeutyczny